Aclaris Therapeutics Inc (NASDAQ: ACRS) On Tuesday, started off the session at the price of On Tuesday, remained unchanged from the previous trading day, before settling in for the closing price of $1.28. Within the past 52 weeks, ACRS’s price has moved between $0.95 and $5.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 72.53% annually for the last half of the decade. The company achieved an average annual earnings per share of 60.09%. With a float of $91.67 million, this company’s outstanding shares have now reached $107.85 million.
In an organization with 64 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 17.43%, operating margin of -728.22%, and the pretax margin is -705.44%.
Aclaris Therapeutics Inc (ACRS) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Aclaris Therapeutics Inc is 15.34%, while institutional ownership is 69.04%. The most recent insider transaction that took place on Nov 19 ’24, was worth 1,499,998. In this transaction Director of this company bought 666,666 shares at a rate of $2.25, taking the stock ownership to the 710,030 shares. Before that another transaction happened on Aug 05 ’24, when Company’s 10% Owner bought 206,025 for $1.24, making the entire transaction worth $256,357. This insider now owns 14,250,000 shares in total.
Aclaris Therapeutics Inc (ACRS) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 60.09% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 19.73% during the next five years compared to 15.24% growth over the previous five years of trading.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Trading Performance Indicators
Aclaris Therapeutics Inc (ACRS) is currently performing well based on its current performance indicators. A quick ratio of 3.99 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.40.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.51, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.74 in one year’s time.
Technical Analysis of Aclaris Therapeutics Inc (ACRS)
Let’s dig in a bit further. During the last 5-days, its volume was 0.57 million. That was inferior than the volume of 0.89 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 53.47%. Additionally, its Average True Range was 0.11.
During the past 100 days, Aclaris Therapeutics Inc’s (ACRS) raw stochastic average was set at 7.80%, which indicates a significant decrease from 48.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 74.14% in the past 14 days, which was higher than the 66.12% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5016, while its 200-day Moving Average is $1.9066. However, in the short run, Aclaris Therapeutics Inc’s stock first resistance to watch stands at $1.3000. Second resistance stands at $1.3200. The third major resistance level sits at $1.3600. If the price goes on to break the first support level at $1.2400, it is likely to go to the next support level at $1.2000. Assuming the price breaks the second support level, the third support level stands at $1.1800.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Key Stats
Market capitalization of the company is 138.60 million based on 108,281K outstanding shares. Right now, sales total 18,720 K and income totals -132,070 K. The company made 9,210 K in profit during its latest quarter, and -96,550 K in sales during its previous quarter.
